Liver's role in cancer drug safety tested
NCT ID NCT07102095
Summary
This study aims to understand how liver disease changes the way the body processes an experimental cancer drug called sevabertinib. Researchers compared about 20 people—half with moderate liver problems and half with healthy livers—after each took a single dose. By measuring drug levels in their blood, the study helps determine if cancer patients with liver issues need adjusted doses for safety and effectiveness.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PHARMACOKINETICS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Clinical Pharmacology of Miami - Oncology
Miami, Florida, 33014, United States
-
Orlando Clinical Research Center
Orlando, Florida, 32809, United States
Conditions
Explore the condition pages connected to this study.